P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC
Martin Schüler(German Cancer Research Center), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Carl Samuelsen(Boehringer Ingelheim (United States)), Caicun Zhou(Tongji University), Nobuyuki Yamamoto(Wakayama Medical University), Kenneth J. O’Byrne(Translational Research Institute), Jean Fan(Johns Hopkins University), Vera Hirsh(Taipei Veterans General Hospital), Sarayut Lucien Geater(Prince of Songkla University), K. Park(Samsung Medical Center), James Chih‐Hsin Yang(National Taiwan University Hospital), Tony Mok(Chinese University of Hong Kong), Chengping Hu(Central South University), Yun Wu, Lecia V. Sequist(Harvard University), Yunchao Huang(North China University of Water Resources and Electric Power), Junming Feng(Jiangsu Cancer Hospital), Angela Märten(Boehringer Ingelheim (United States)), Shun Lü(Shanghai Jiao Tong University), Stuart H. Ellis(Cheshire West and Chester), E.H. Tan(National Cancer Centre Singapore)
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k